{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T16:30:02Z","timestamp":1768753802790,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T00:00:00Z","timestamp":1260489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00228-009-0760-2","type":"journal-article","created":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T13:14:38Z","timestamp":1260450878000},"page":"275-283","source":"Crossref","is-referenced-by-count":17,"title":["In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A"],"prefix":"10.1007","volume":"66","author":[{"given":"Thomas M.","family":"Polasek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janani S.","family":"Sadagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,11]]},"reference":[{"key":"760_CR1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/17425255.3.3.321","volume":"3","author":"TM Polasek","year":"2007","unstructured":"Polasek TM, Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3:321\u2013329","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"760_CR2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","volume":"28","author":"BS Mayhew","year":"2000","unstructured":"Mayhew BS, Jones DR, Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031\u20131037","journal-title":"Drug Metab Dispos"},{"key":"760_CR3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/dmd.31.7.945","volume":"31","author":"K Ito","year":"2003","unstructured":"Ito K, Ogihara K, Kanamitsu S, Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945\u2013954","journal-title":"Drug Metab Dispos"},{"key":"760_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"M Jamei","year":"2009","unstructured":"Jamei M, Dickinson GL, Rostami-Hodjegan A (2009) A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrated general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of \u2018bottom-up\u2019 vs \u2018top-down\u2019 recognition of covariates. Drug Metab Pharmacokinet 24:53\u201375","journal-title":"Drug Metab Pharmacokinet"},{"key":"760_CR5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1007572803027","volume":"17","author":"S Kanamitsu","year":"2000","unstructured":"Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y (2000) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419\u2013426","journal-title":"Pharm Res"},{"key":"760_CR6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","volume":"35","author":"RS Obach","year":"2007","unstructured":"Obach RS, Walsky RL, Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246\u2013255","journal-title":"Drug Metab Dispos"},{"key":"760_CR7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1124\/dmd.108.022178","volume":"37","author":"X Zhang","year":"2009","unstructured":"Zhang X, Jones DR, Hall SD (2009) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 37:150\u2013160","journal-title":"Drug Metab Dispos"},{"key":"760_CR8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","volume":"34","author":"A Galetin","year":"2006","unstructured":"Galetin A, Burt H, Gibbons L, Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166\u2013175","journal-title":"Drug Metab Dispos"},{"key":"760_CR9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","volume":"37","author":"OA Fahmi","year":"2009","unstructured":"Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data; predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658\u20131666","journal-title":"Drug Metab Dispos"},{"key":"760_CR10","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","volume":"36","author":"OA Fahmi","year":"2008","unstructured":"Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698\u20131708","journal-title":"Drug Metab Dispos"},{"key":"760_CR11","first-page":"1257","volume":"37","author":"HJ Einolf","year":"2007","unstructured":"Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257\u20131294","journal-title":"Xenobiotica"},{"key":"760_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejps.2008.10.002","volume":"36","author":"KH Grime","year":"2009","unstructured":"Grime KH, Bird J, Ferguson D, Riley RJ (2009) Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175\u2013191","journal-title":"Eur J Pharm Sci"},{"key":"760_CR13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","volume":"37","author":"SW Grimm","year":"2009","unstructured":"Grimm SW, Einolf HJ, Hall SD, He K, Lim H-K, Ling K-H, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ, Obach RS (2009) The conduct of in vitro studies to address time-dependent inhibition of drug metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America (PhRMA). Drug Metab Dispos 37:1355\u20131370","journal-title":"Drug Metab Dispos"},{"key":"760_CR14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17425255.3.1.51","volume":"3","author":"RJ Riley","year":"2007","unstructured":"Riley RJ, Grime K, Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51\u201366","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"760_CR15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/138920007780866861","volume":"8","author":"K Venkatakrishnan","year":"2007","unstructured":"Venkatakrishnan K, Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Current Drug Metab 8:449\u2013462","journal-title":"Current Drug Metab"},{"key":"760_CR16","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/00498250701670945","volume":"37","author":"K Venkatakrishnan","year":"2007","unstructured":"Venkatakrishnan K, Obach RS, Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225\u20131256","journal-title":"Xenobiotica"},{"key":"760_CR17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0090-9556(25)06824-2","volume":"23","author":"L Pichard","year":"1995","unstructured":"Pichard L, Gillet G, Bonfils C, Domergue J, Th\u00e9not J-P, Maurel P (1995) Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab Dispos 23:1253\u20131262","journal-title":"Drug Metab Dispos"},{"key":"760_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2125.1999.00953.x","volume":"48","author":"LL Moltke von","year":"1999","unstructured":"von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI (1999) Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 48:89\u201397","journal-title":"Br J Clin Pharmacol"},{"key":"760_CR19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(98)90057-1","volume":"64","author":"DJ Greenblatt","year":"1998","unstructured":"Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol AL, Counihan M, Roth-Schechter BF, Shader RI (1998) Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 64:661\u2013671","journal-title":"Clin Pharmacol Ther"},{"key":"760_CR20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0009-9236(97)90082-5","volume":"62","author":"K Villikka","year":"1997","unstructured":"Villikka K, Kivist\u00f6 KT, Luurila H, Neuvonen PJ (1997) Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 62:629\u2013634","journal-title":"Clin Pharmacol Ther"},{"key":"760_CR21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.2006.02707.x","volume":"63","author":"TI Saari","year":"2007","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2007) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 63:116\u2013120","journal-title":"Br J Clin Pharmacol"},{"key":"760_CR22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/clpt.2008.293","volume":"85","author":"D Farkas","year":"2009","unstructured":"Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ (2009) Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 85:644\u2013650","journal-title":"Clin Pharmacol Ther"},{"key":"760_CR23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00023210-200317070-00004","volume":"17","author":"LM Hesse","year":"2003","unstructured":"Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17:513\u2013532","journal-title":"CNS Drugs"},{"key":"760_CR24","first-page":"617","volume":"26","author":"S Allard","year":"1998","unstructured":"Allard S, Sainati SM, Roth-Schechter BF, MacIntyre J (1998) Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 26:617\u2013622","journal-title":"Drug Metab Dispos"},{"key":"760_CR25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/00912709922007624","volume":"39","author":"S Allard","year":"1999","unstructured":"Allard S, Sainati SM, Roth-Schechter BF (1999) Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 39:184\u2013191","journal-title":"J Clin Pharmacol"},{"key":"760_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.clpt.6100211","volume":"82","author":"RM Cysneiros","year":"2007","unstructured":"Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ (2007) Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther 82:54\u201362","journal-title":"Clin Pharmacol Ther"},{"key":"760_CR27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0306-3623(95)02014-4","volume":"27","author":"JO Miners","year":"1996","unstructured":"Miners JO, Birkett DJ (1996) The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 27:245\u2013249","journal-title":"Gen Pharmacol"},{"key":"760_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/bdd.329","volume":"23","author":"LL Moltke von","year":"2002","unstructured":"von Moltke LL, Weemhoff JL, Perloff MD, Hesse LM, Harmatz JS, Roth-Schechter BF, Greenblatt DJ (2002) Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 23:361\u2013367","journal-title":"Biopharm Drug Dispos"},{"key":"760_CR29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-007-0327-z","volume":"63","author":"S Bomsien","year":"2007","unstructured":"Bomsien S, Skopp G (2007) An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol 63:821\u2013827","journal-title":"Eur J Clin Pharmacol"},{"key":"760_CR30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00228-005-0091-x","volume":"62","author":"TM Polasek","year":"2006","unstructured":"Polasek TM, Miners JO (2006) Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A probe substrate. Eur J Clin Pharmacol 62:203\u2013208","journal-title":"Eur J Clin Pharmacol"},{"key":"760_CR31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2165\/00003088-199223020-00004","volume":"23","author":"P Periti","year":"1992","unstructured":"Periti P, Mazzei T, Mini E, Novelli A (1992) Pharmacokinetic drug interactions of macrolides [erratum appears in Clin Pharmacokinet 1993 Jan;24(1):70]. Clin Pharmacokinet 23:106\u2013131","journal-title":"Clin Pharmacokinet"},{"key":"760_CR32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/138920006776359293","volume":"7","author":"K Ghanbari","year":"2006","unstructured":"Ghanbari K, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism-based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Current Drug Metab 7:315\u2013334","journal-title":"Current Drug Metab"},{"key":"760_CR33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejps.2007.04.005","volume":"31","author":"J Yang","year":"2007","unstructured":"Yang J, Jamei M, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A (2007) Theoretical assessment of a new experimental protocol for determining kinetc values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci 31:232\u2013241","journal-title":"Eur J Pharm Sci"},{"key":"760_CR34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","volume":"60","author":"K Bowalgaha","year":"2005","unstructured":"Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423\u2013433","journal-title":"Br J Clin Pharmacol"},{"key":"760_CR35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1124\/jpet.104.071803","volume":"311","author":"TM Polasek","year":"2004","unstructured":"Polasek TM, Elliot DJ, Lewis BC, Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996\u20131007","journal-title":"J Pharmacol Exp Ther"},{"key":"760_CR36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2125.2006.02627.x","volume":"61","author":"TM Polasek","year":"2006","unstructured":"Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO (2006) An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570\u2013584","journal-title":"Br J Clin Pharmacol"},{"key":"760_CR37","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#","volume":"89","author":"TS Maurer","year":"2000","unstructured":"Maurer TS, Tabrizi-Fard MA, Fung H-L (2000) Impact of mechanism-based enzyme inactivation on inhibitory potency: implications for rational drug discovery. J Pharm Sci 89:1404\u20131414","journal-title":"J Pharm Sci"},{"key":"760_CR38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/187231208783478407","volume":"2","author":"LM Berry","year":"2008","unstructured":"Berry LM, Zhao Z (2008) An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2:51\u201359","journal-title":"Drug Metab Lett"},{"key":"760_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425250802691074","volume":"5","author":"M Jamei","year":"2009","unstructured":"Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:1\u201313","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"760_CR40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.32.10.1083","volume":"32","author":"DJ McConn 2nd","year":"2004","unstructured":"McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083\u20131091","journal-title":"Drug Metab Dispos"},{"key":"760_CR41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/dmd.104.001834","volume":"33","author":"Y Wang","year":"2005","unstructured":"Wang Y, Jones DR, Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664\u2013671","journal-title":"Drug Metab Dispos"},{"key":"760_CR42","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan LS, Grimm SW, Kao J, King SP, Miwa G, Ni L, Kumar GN, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815\u2013832","journal-title":"Drug Metab Dispos"},{"key":"760_CR43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","volume":"316","author":"RS Obach","year":"2006","unstructured":"Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336\u2013348","journal-title":"J Pharmacol Exp Ther"},{"key":"760_CR44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s002280000125","volume":"56","author":"LL Moltke von","year":"2000","unstructured":"von Moltke LL, Durol AL, Duan SX, Greenblatt DJ (2000) Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 56:259\u2013261","journal-title":"Eur J Clin Pharmacol"},{"key":"760_CR45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","volume":"29","author":"P Salv\u00e0","year":"1995","unstructured":"Salv\u00e0 P, Costa J (1995) Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 29:142\u2013153","journal-title":"Clin Pharmacokinet"},{"key":"760_CR46","first-page":"369","volume-title":"Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach","author":"H Albin","year":"1988","unstructured":"Albin H, Vincon G, Vincon J, Hermann P, Thiercelin JF (1988) Study of the pharmacokinetics of zolpidem in healthy volunteers after repeated administration: effects on antipyrine clearance. In: Sauvanet JP, Langer SZ, Morselli PL (eds) Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. Raven Press, New York, pp 369\u2013370"},{"key":"760_CR47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","volume":"76","author":"ED Kharasch","year":"2004","unstructured":"Kharasch ED, Hoffer C, Whittington D, Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250\u2013269","journal-title":"Clin Pharmacol Ther"},{"key":"760_CR48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/03602530701836704","volume":"40","author":"WW Johnson","year":"2008","unstructured":"Johnson WW (2008) Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance. Drug Metab Rev 40:101\u2013147","journal-title":"Drug Metab Rev"},{"key":"760_CR49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2125.2007.02964.x","volume":"65","author":"TM Polasek","year":"2008","unstructured":"Polasek TM, Miners JO (2008) Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 65:87\u201397","journal-title":"Br J Clin Pharmacol"},{"key":"760_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0090-9556(24)15118-5","volume":"28","author":"B Ma","year":"2000","unstructured":"Ma B, Prueksaritanont T, Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125\u2013130","journal-title":"Drug Metab Dispos"},{"key":"760_CR51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0076-6879(91)06126-N","volume":"206","author":"MR Franklin","year":"1991","unstructured":"Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559\u2013573","journal-title":"Methods Enzymol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0760-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0760-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T19:16:36Z","timestamp":1739474196000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0760-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,11]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0760-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,11]]}}}